Clinical Trial, Phase III Randomized Controlled Trial Letter Ppublish 15 citations
PubMed: 37170037 DOI: 10.1245/s10434-023-13500-9
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2).
Ann Surg Oncol 30(8):4573-4575
Authors: Jacob Lambdin, Carrie Ryan, Stephanie Gregory, Kenneth Cardona, Jonathan M Hernandez, Winan J van Houdt, Alessandro Gronchi
Affiliations
- Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital Midtown, Atlanta, Georgia, USA.
- Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam, The Netherlands.
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133, Milan, Italy.
MeSH
Sarcoma, Risk, Drug Therapy, Chemotherapy
Cited by
- Perioperative Systemic Therapy in Rare, Chemosensitive Subtypes of Retroperitoneal Sarcoma: A Hospital-Based Propensity Score-Matched Analysis. Cancers (Basel), 2025
- The Role of [ 18F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas. Curr Oncol, 2025
- Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target. Int J Mol Sci, 2025